covi-drops
mAbexperimentalCOVID-19
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jul 18, 2021 (NCT04900428)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Spike glycoproteinANTAGONIST
Spike glycoprotein antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05074394 | Phase 2 | Nov 30, 2021 | Sorrento Therapeutics, Inc. |
| NCT04906694 | Phase 2 | Oct 31, 2021 | Sorrento Therapeutics, Inc. |
| NCT04900428 | Phase 2 | Jul 18, 2021 | Sorrento Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sorrento Therapeutics, Inc. | For profit | 3 | 3 | 1 | 2021 |
1 organizations
Page 1 / 1